PRME
Prime Medicine, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$660.82M
P/E Ratio
—
EPS
$-1.35
Beta
2.67
52W High
$6.94
52W Low
$1.11
50-Day MA
$3.65
200-Day MA
$4.06
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc. is a pioneering biotechnology firm that aims to transform healthcare with its groundbreaking Prime Editing technology, designed for accurate genetic modifications at the DNA level. The company is advancing a strong pipeline of innovative therapies targeting serious diseases, such as genetic disorders and cancer, backed by exceptional intellectual property protections. Committed to addressing critical unmet medical needs, Prime Medicine is strategically positioned to be a key player in the genetic medicine arena, showing significant potential for growth and a meaningful contribution to the evolving biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | $4.63M |
| Gross Profit (TTM) | $-156.00M |
| EBITDA | $-201.03M |
| Operating Margin | -5800.00% |
| Return on Equity | -146.80% |
| Return on Assets | -40.70% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.68 |
| Price-to-Book | 5.12 |
| Price-to-Sales (TTM) | 142.66 |
| EV/Revenue | 120.48 |
| EV/EBITDA | -3.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -61.60% |
| Shares Outstanding | $180.55M |
| Float | $105.20M |
| % Insiders | 23.77% |
| % Institutions | 64.47% |
Historical Volatility
HV 10-Day
78.60%
HV 20-Day
69.14%
HV 30-Day
67.30%
HV 60-Day
83.06%
HV Rank
1.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($6.92 target)
1
Strong Buy8
Buy4
HoldData last updated: 4/14/2026